Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delgocitinib cream for Chronic Hand Eczema (DELTA 2)
NCT04872101Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- May 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in chronic hand eczema (CHE) comparing Delgocitinib Cream with Vehicle Cream (2 arms). Primary endpoint: Investigator's Global Assessment for Chronic Hand Eczema Treatment Success at 16 weeks. Started May 2021; status: completed.
02
Drugs
delgocitinib
03
Conditions
chronic hand eczema (CHE)
Beyond the preview
Go deeper on NCT04872101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04872101.